Best of ASCO - 2014 Annual Meeting

 

Welcome

Hodgkin Lymphoma

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A meta-analysis on ABVD administration in HIV+ patients with advanced stage Hodgkin’s lymphoma (HL).

Kritika Subramanian

e19522

Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.

Rod Ramchandren

7541

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).

Robert W. Chen

7539

Clinical outcome of Hodgkin lymphoma: A single center study.

Sharareh Seifi

e19515

Clinicopathological features and prediction values of HDAC1, 2, 3 and 11 in classical Hodgkin lymphoma.

Xiaojian Liu

e19518

Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma.

Ayla Gokmen

e19517

Hodgkin lymphoma: The Moffitt Cancer Center Experience.

Ashley Rose

e19516

Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.

Catherine S. Magid Diefenbach

7538

Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma.

David J. Straus

7534

KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.

Christine Mauz-Korholz

TPS7583

Limited stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): A subgroup analysis of the HD.6 clinical trial.

Bethany Monteith

7535

Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

Jonathan W. Friedberg

7542

Phase I/II study to evaluate the safety and efficacy of tenalisib, a novel PI3K δ/γ dual inhibitor in combination with pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma.

Rod Ramchandren

TPS7584

Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study.

Andrew M. Evens

7540

Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: Final analysis of the AHL2011 LYSA study.

Olivier Casasnovas

7503

Safety and efficacy of decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin lymphoma.

Chunmeng Wang

7537

Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).

Yuankai Shi

7536

Survival by age in children and adolescents with Hodgkin lymphoma: A pooled analysis of Children’s Oncology Group (COG) trials.

Justine M. Kahn

7543